Sign In
Buy PBYI
$8.04
+0.380 (+4.96%)
At Close: Jun 23, 2026
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:05pm, Wednesday, 05'th Feb 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 4, 2025, the Compensation Committee of Puma's Board of Directors approved
Best Momentum Stocks to Buy for January 6th
11:35am, Monday, 06'th Jan 2025
NRXP, PDEX and PBYI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 6, 2024.
Best Value Stocks to Buy for January 6th
04:01am, Monday, 06'th Jan 2025
AHT, PBYI and CWD made it to the Zacks Rank #1 (Strong Buy) value stocks list on January 6, 2024.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:15pm, Friday, 03'rd Jan 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on January 2, 2025, the Compensation Committee of Puma's Board of Directors approved
All You Need to Know About Puma Biotech (PBYI) Rating Upgrade to Strong Buy
01:15pm, Wednesday, 01'st Jan 2025
Puma Biotech (PBYI) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Puma Biotechnology (PBYI) Stock Undervalued Right Now?
10:51am, Wednesday, 01'st Jan 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why
11:11am, Friday, 27'th Dec 2024
Sales of PBYI's sole-marketed drug, Nerlynx exceeded management's expectations in the third quarter. Also, the acquisition of alisertib holds promise.
Best Momentum Stocks to Buy for December 24th
11:16am, Tuesday, 24'th Dec 2024
PBYI, DDS and NJR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 24, 2024.
New Strong Buy Stocks for December 24th
06:51am, Tuesday, 24'th Dec 2024
FTI, NRXP, PBYI, POWL and VMEO have been added to the Zacks Rank #1 (Strong Buy) List on December 24, 2024.
Best Value Stocks to Buy for December 24th
04:16am, Tuesday, 24'th Dec 2024
PBYI, DDS and PINC made it to the Zacks Rank #1 (Strong Buy) value stocks list on December 24, 2024.
LOS ANGELES--(BUSINESS WIRE)--NCCN Guidelines for Cervical Cancer now include Puma's neratinib monotherapy for 2nd line or later use in patients with HER2-mutated tumors, Cat. 2A.
Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward
11:36am, Monday, 16'th Dec 2024
Puma Biotechnology focuses on expanding neratinib sales and developing alisertib for breast and lung cancers, despite recent stock declines. Neratinib sales are stagnant, but the company remains stabl
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:15pm, Wednesday, 04'th Dec 2024
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced the grant of an inducement award to a November new hire, as required under Nasdaq Listing Rule 5635(c)(4).
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?
10:41am, Thursday, 28'th Nov 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer
12:16pm, Thursday, 21'st Nov 2024
Puma Biotechnology starts the phase II ALISCA-Breast1 study on alisertib for treating hormone receptor-positive, HER2-negative metastatic breast cancer.
